Brokers Offer Predictions for TPST Q1 Earnings

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for Tempest Therapeutics in a research report issued to clients and investors on Friday, March 28th. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.34) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share.

Separately, Scotiabank decreased their price target on shares of Tempest Therapeutics from $13.00 to $7.00 and set a “sector outperform” rating on the stock in a research note on Friday.

Tempest Therapeutics Trading Down 8.1 %

TPST opened at $0.77 on Monday. The stock’s 50 day simple moving average is $0.87 and its 200-day simple moving average is $0.97. The stock has a market cap of $33.70 million, a PE ratio of -0.50 and a beta of -1.83. Tempest Therapeutics has a 1 year low of $0.70 and a 1 year high of $6.00.

Tempest Therapeutics (NASDAQ:TPST) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.07). The company had revenue of $0.49 million during the quarter.

Institutional Investors Weigh In On Tempest Therapeutics

Several large investors have recently modified their holdings of the stock. XTX Topco Ltd bought a new position in shares of Tempest Therapeutics during the 3rd quarter worth approximately $34,000. Virtu Financial LLC acquired a new position in Tempest Therapeutics during the fourth quarter worth $36,000. Northern Trust Corp raised its stake in Tempest Therapeutics by 233.2% during the fourth quarter. Northern Trust Corp now owns 67,815 shares of the company’s stock worth $57,000 after acquiring an additional 47,461 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Tempest Therapeutics by 42.7% during the third quarter. Geode Capital Management LLC now owns 220,067 shares of the company’s stock valued at $308,000 after acquiring an additional 65,826 shares during the period. Finally, Millennium Management LLC acquired a new stake in shares of Tempest Therapeutics in the 4th quarter valued at $158,000. 22.52% of the stock is currently owned by institutional investors.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.